国新健康保障服务集团股份有限公司 董事会 2024 年度工作报告 2024 年度，国新健康保障服务集团股份有限公司（以下简称"公司"）董 事会按照《中华人民共和国公司法》（以下简称《公司法》）《国新健康保障服 务集团股份有限公司章程》（以下简称《公司章程》）及《董事会议事规则》的 相关规定，切实履行职责，勤勉尽责，强化执行，圆满完成了各项工作，进一步 规范、优化了公司法人治理结构，确保董事会科学决策和规范运作，为保障公司 和全体股东利益、推动公司持续健康发展发挥了重要作用，现将 2024 年度董事 会工作报告如下： 一、董事会会议召开情况 2024 年度，共召开 12 次董事会会议，共审议通过 51 项议案，议案涉及修 订及制定公司治理制度、募集资金使用与管理、关联交易、定期报告、向银行申 请综合授信额度、回购注销限制性股票、补选董事、变更法定代表人、调整公司 架构、聘任会计师事务所等事项。会议的召开程序均符合《公司法》等法律法规 以及《公司章程》的相关规定，会议形成的决议合法、有效。具体情况如下： | 序号 | 召开时间 | | 会议届次 | 议案 | | --- | --- | --- | --- | - ...

国新健康保障服务集团股份有限公司 2024 年度募集资金年度存放与使用情况专项报告 根据中国证监会发布的《上市公司监管指引第 2 号——上市公司募集资金管 理和使用的监管要求》（证监会公告[2012]44 号）和深圳证券交易所发布的《深 圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等有关 规定，国新健康保障服务集团股份有限公司（以下简称"公司"或"本公司"）董事 会编制了截至 2024 年 12 月 31 日止的募集资金年度存放与实际使用情况的专项 报告。 一、募集资金基本情况 中国证券监督管理委员会于 2023 年 8 月 23 日出具了《关于同意国新健康保 障服务集团股份有限公司向特定对象发行股票注册的批复》（证监许可〔2023〕 1899 号），同意公司向特定对象发行股票的注册申请。 公司本次向特定对象发行股票 80,413,268 股，发行价格为 9.88 元/股。根据 大信会计师事务所（特殊普通合伙）出具的《国新健康保障服务集团股份有限公 司向特定对象发行股票募集资金验资报告》（23-00006 号），截至 2023 年 11 月 17 日止，公司向特定对象实际发行 A 股股 ...

Financial Performance - The company's revenue for Q1 2025 was ¥50,467,725.80, representing a 5.33% increase compared to ¥47,915,544.20 in the same period last year[3]. - The net profit attributable to shareholders was -¥45,576,538.97, a decrease of 12.86% from -¥40,381,786.35 year-over-year[3]. - The total operating revenue for the current period is CNY 50,467,725.80, an increase from CNY 47,915,544.20 in the previous period, representing a growth of approximately 5.5%[24]. - The net profit for the current period is -45,576,538.97, compared to -40,380,236.63 in the previous period, indicating a decline of approximately 12.5%[25]. - The total comprehensive income for the current period is -45,593,839.33, compared to -40,355,707.49 in the previous period, reflecting a decrease of about 13.5%[25]. - The basic and diluted earnings per share for the current period are both -0.0465, compared to -0.0412 in the previous period, indicating a worsening of approximately 8.0%[26]. Cash Flow and Assets - The net cash flow from operating activities improved by 34.66%, reaching -¥65,632,343.86 compared to -¥100,443,543.19 in the previous year[3]. - The company's cash and cash equivalents decreased to CNY 365,780,927.32 from CNY 451,840,676.26, a decline of about 19%[20]. - Cash and cash equivalents at the end of the period stand at 351,391,328.46, down from 816,969,617.12 at the end of the previous period, a decrease of about 56.9%[27]. - The operating cash flow for the current period is -65,632,343.86, an improvement from -100,443,543.19 in the previous period, showing a reduction in cash outflow by approximately 34.7%[26]. Assets and Liabilities - Total assets decreased by 3.35% to ¥1,992,785,005.50 from ¥2,061,938,679.96 at the end of the previous year[3]. - The total assets of the company as of March 31, 2025, are CNY 1,992,785,005.50, down from CNY 2,061,938,679.96 at the beginning of the period, reflecting a decrease of approximately 3.3%[22]. - The total liabilities decreased to CNY 632,772,661.63 from CNY 656,332,496.76, a reduction of about 3.6%[22]. - The company's total equity decreased to CNY 1,360,012,343.87 from CNY 1,405,606,183.20, indicating a decline of approximately 3.2%[22]. Investments and Expenses - Investment income surged by 212.51% to ¥4,320,158.46, attributed to the growth in net profits of joint ventures and interest income from large bank deposits[8]. - The total operating costs for the current period amount to CNY 101,542,262.28, up from CNY 90,887,714.68 in the previous period, indicating an increase of about 11.5%[24]. - Sales expenses increased by 35.28% to ¥14,923,130.53, reflecting higher investments in market development and sales personnel costs[8]. - The company incurred credit impairment losses of 3,398,061.31, which is significantly higher than 1,795,408.37 in the previous period, marking an increase of approximately 89.2%[25]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 70,199[10]. - The largest shareholder, China Oceanwide Holdings Group Co., Ltd., holds 24.02% of the shares, totaling 235,702,593 shares[10]. Corporate Governance - The company appointed Mr. Zhang Zhenhua as the vice president, effective immediately upon board approval[14]. - The company held a board meeting to elect candidates for the twelfth board of directors, including both independent and non-independent directors[15]. - The company has elected a new employee representative supervisor, Ms. Xia Kun, to join the newly formed 12th Supervisory Board[17]. - The company has proposed the nomination of two shareholder representative supervisors for the 12th Supervisory Board, pending approval[16]. - The company approved the repurchase and cancellation of 125,800 restricted stocks due to three individuals no longer meeting incentive conditions[13]. Organizational Changes - The company restructured its organization by dissolving the PBG Data R&D Department and establishing an AI Center to oversee AI infrastructure development[14]. - The company decided to continue using RMB 450 million of temporarily idle raised funds for cash management until January 28, 2026[13].

Financial Performance - The company's operating revenue for 2024 was CNY 356,896,420.31, representing an increase of 8.11% compared to CNY 330,126,718.06 in 2023[19]. - The net profit attributable to shareholders for 2024 was a loss of CNY 10,375,438.31, an improvement of 87.00% from a loss of CNY 79,791,984.63 in 2023[19]. - The net cash flow from operating activities improved to a negative CNY 82,489,277.85 in 2024, a 19.30% increase from a negative CNY 102,215,067.80 in 2023[19]. - The basic earnings per share for 2024 was -0.0106, showing an improvement of 87.90% from -0.0876 in 2023[19]. - Total assets at the end of 2024 were CNY 2,061,938,679.96, a 5.66% increase from CNY 1,951,543,466.24 at the end of 2023[19]. - The net assets attributable to shareholders decreased by 1.03% to CNY 1,405,606,183.20 at the end of 2024 from CNY 1,420,251,225.49 at the end of 2023[19]. - The company has reported a decrease in net profit after deducting non-recurring gains and losses, with a loss of CNY 151,674,390.39 in 2024 compared to a loss of CNY 115,760,381.59 in 2023, a decline of 31.02%[19]. Cash Flow and Investment - The company reported a significant difference between net cash flow from operating activities and net profit, with a net cash flow of -¥82,489,277.85 and a net profit of -¥11,466,500[83]. - Investment income amounted to ¥143,019,379.11, representing 1,223.17% of total profit, primarily from equity investment disposals and equity method accounting for joint ventures[85]. - Fair value changes resulted in a gain of ¥6,340,000.00, accounting for 54.22% of total profit, mainly from the fair value changes of held financial assets[85]. - Cash and cash equivalents decreased by 25.65% to ¥451,840,676.26, down from ¥928,057,174.89, due to cash management of temporarily idle raised funds[87]. - The company raised a total of RMB 794,483,087.84 through the issuance of 80,413,268 shares at a price of RMB 9.88 per share[97]. - The company has not yet utilized the remaining funds for temporary liquidity support, which are currently held in a demand deposit account[98]. Digital Healthcare Initiatives - The company is focused on digital healthcare, emphasizing the integration of AI and big data in its services to enhance medical insurance fund management and healthcare quality[30]. - The digital medical insurance business aims to provide standardized and intelligent support systems for medical insurance payment and supervision, enhancing the efficiency of fund utilization[30]. - The company is actively involved in the development of a multi-level medical security system, aligning with national healthcare reforms to improve service delivery[29]. - The introduction of DRG payment services is designed to optimize the payment process for medical institutions, promoting better resource allocation and efficiency[31]. - The company is leveraging AI and big data to establish a disease classification system that supports local healthcare needs and enhances payment accuracy[32]. Research and Development - The company is focusing on upgrading its R&D center, which includes the first and second phases of data platform upgrades, aiming to enhance AI-based medical knowledge graphs and support various business R&D efforts[76]. - The number of R&D personnel decreased by 25.35% from 651 in 2023 to 486 in 2024[77]. - R&D investment amount decreased by 39.16% from ¥49,062,327.32 in 2023 to ¥29,849,857.42 in 2024[78]. - The proportion of R&D investment to operating revenue fell by 6.50% from 14.86% in 2023 to 8.36% in 2024[78]. Corporate Governance and Management Changes - The company has a complete and independent organizational structure, ensuring no mixed operations with controlling shareholders[126]. - The company appointed Yuan Hongquan as the new General Manager on April 25, 2024, after he transitioned from the position of Deputy General Manager[131]. - The company experienced a management change with the resignation of several executives, including Sun Di Cao and Sun Li Qun, due to personal reasons[131]. - The company’s board of directors held a meeting on April 25, 2024, to approve the management changes and discuss future strategies[131]. - The company has engaged in multiple investor communications throughout 2024 to discuss overall performance and future business plans[117]. Environmental and Social Responsibility - The company has published its 2024 ESG report detailing its social responsibility initiatives[173]. - The company is not classified as a key pollutant discharge unit by environmental protection authorities[171]. - No administrative penalties were imposed on the company or its subsidiaries for environmental issues during the reporting period[171]. - The company has taken measures to reduce carbon emissions, although specific details were not disclosed[172]. Market Expansion and Strategic Focus - The company has identified key areas for market expansion, particularly in health services, aiming for a 20.7% growth in this segment[101]. - The company is exploring potential acquisitions to enhance its service offerings and market presence, with a focus on strategic partnerships[101]. - The company aims to transform into a leading health data service provider by leveraging information technology, digitalization, and AI models to enhance customer value[112]. - The strategic focus includes implementing a "smart innovation" strategy to become a data-driven enterprise in the healthcare sector, particularly in the "three medical" fields[112]. Financial Management and Compliance - The company has established a financial service agreement with Guoxin Group Financial Co., Ltd. to handle daily fund settlements, deposits, and loans, which was approved in the board meeting on May 21, 2024[198]. - The maximum daily deposit limit with Guoxin Group Financial Co., Ltd. is RMB 50 million, with an interest rate of 0.525%[195]. - The company has not engaged in any significant related party transactions during the reporting period[191]. - The company has not experienced any major litigation or arbitration matters during the reporting period[189].

监事会对公司 2024 年度内部控制评价报告的意见 根据《企业内部控制基本规范》等有关文件的要求，作为公司监事，本着谨 慎的原则，我们对公司《2024 年度内部控制评价报告》进行了审阅，发表意见 如下： 《2024 年度内部控制评价报告》的形式、内容符合有关法律、法规、规范 性文件的要求，报告真实、准确、完整地反映了公司 2024 年度内部控制的实际 情况，公司内部控制保证了公司经营的合法、合规及公司内部规章制度的贯彻执 行。2024 年，公司未有违反《企业内部控制应用指引》及公司内部控制制度的 情形发生。监事会对公司《2024 年度内部控制评价报告》不存在异议。 国新健康保障服务集团股份有限公司 监 事 会 二零二五年四月二十四日 国新健康保障服务集团股份有限公司 ...

证券简称：国新健康 证券代码：000503 编号：2025-20 国新健康保障服务集团股份有限公司 第十一届监事会第二十八次会议暨2024年度会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 国新健康保障服务集团股份有限公司（以下简称"公司"）第十一届监事 会第二十八次会议暨2024年度会议于2025年4月11日发出会议通知，会议由监事 会主席周蔚女士召集并主持，于2025年4月23日以现场结合通讯方式召开。本次 会议应出席监事3人，实际出席监事3人。会议的召开符合有关法律、行政法规、 部门规章和《公司章程》规定。 本次会议以记名投票方式表决，审议通过了如下议案： 一、公司 2024 年年度报告及摘要 经审核，监事会认为董事会编制和审议公司 2024 年年度报告的程序符合法 律、行政法规、中国证监会和深圳证券交易所的相关规定，报告内容能够真实、 准确、完整地反映上市公司的实际情况，不存在任何虚假记载、误导性陈述或 者重大遗漏。 表决结果：3 票赞成，0 票反对，0 票弃权。 本议案尚需提交公司股东大会审议。 具体内容详见同日在巨潮资讯网（网址：ww ...

证券简称：国新健康 证券代码：000503 编号：2025-19 国新健康保障服务集团股份有限公司 第十一届董事会第三十八次会议暨2024年度会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 国新健康保障服务集团股份有限公司（以下简称"公司"）第十一届董事 会第三十八次会议暨 2024 年度会议于 2025 年 4 月 11 日发出会议通知，会议由 董事长李永华先生召集并主持，于 2025 年 4月 23 日以现场结合通讯方式召开。 本次会议应出席董事 8 人，实际出席董事 8 人，公司监事和高级管理人员列席 会议。会议的召开符合有关法律、行政法规、部门规章和《公司章程》规定。 本次会议以记名投票方式表决，审议通过了如下议案： 一、公司 2024 年年度报告及摘要 表决结果：8 票赞成，0 票反对，0 票弃权。 本议案尚需提交公司股东大会审议。 具体内容详见同日在巨潮资讯网（网址：www.cninfo.com.cn）披露的 《2024 年年度报告》，以及在《中国证券报》《上海证券报》《证券时报》及 巨潮资讯网（网址：www.cninfo.com.c ...

证券简称：国新健康 证券代码：000503 编号：2025-23 国新健康保障服务集团股份有限公司 关于 2024 年度拟不进行利润分配的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 国新健康保障服务集团股份有限公司（以下简称"公司"）于2025年4月23 日召开的第十一届董事会第三十八次会议暨2024年度会议，以8票赞成、0票反对、 0票弃权，审议通过了《公司2024年度利润分配预案》；同日召开的第十一届监 事会第二十八次会议暨2024年度会议，以3票赞成、0票反对、0票弃权，审议通 过了《公司2024年度利润分配预案》，本议案尚需提交公司2024年度股东大会审 议，具体情况如下： 公司连续三个会计年度净利润为负值，不进行现金分红符合相关规定。因此 公司不触及《深圳证券交易所股票上市规则》第 9.8.1 条规定的可能被实施其他 风险警示的情形。 一、利润分配预案基本情况 经中证天通会计师事务所（特殊普通合伙）审计，公司 2024 年度实现归属 于上市公司股东的净利润为-10,375,438.31 元，归属于上市公司股东的扣除非经 常性损益的净利润-1 ...

本次股东大会的议案6.00需经出席会议的股东所持表决权的三分之二以上通过，其他议案需经出席会议 的股东所持表决权的二分之一以上通过。其中，议案6.00，公司限制性股票激励计划（第一期）的激励 对象作为关联股东，对该议案回避表决。 国新健康保障服务集团股份有限公司（以下简称"公司"）于2025年3月26日召开第十一届董事会第三十 七次会议，审议通过了《关于召开公司2025年第一次临时股东大会的议案》，公司已于2025年4月16日 在《中国证券报》《上海证券报》《证券时报》及巨潮资讯网（网址：www.cninfo.com.cn）发布了 《关于召开2025年第一次临时股东大会的通知》（公告编号：2025-17）。为了保护投资者的合法权 益，方便公司股东行使股东大会表决权，现发布关于召开2025年第一次临时股东大会的提示性公告。具 体内容公告如下： 一、召开会议的基本情况 （一）股东大会届次：2025年第一次临时股东大会 特别提示： 本次股东大会的议案1.00至议案3.00采用累积投票方式进行投票，本次应选非独立董事6名，应选独立董 事3名，应选股东代表监事2名。股东所拥有的选举票数为其所持有表决权的股份数量乘以应选 ...

证券简称：国新健康 证券代码：000503 编号：2025-18 国新健康保障服务集团股份有限公司 关于召开 2025 年第一次临时股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 本次股东大会的议案 1.00 至议案 3.00 采用累积投票方式进行投票，本次应 选非独立董事 6 名，应选独立董事 3 名，应选股东代表监事 2 名。股东所拥有的 选举票数为其所持有表决权的股份数量乘以应选人数，股东可以将所拥有的选 举票数以应选人数为限在议案中任意分配（可以投出零票），但总数不得超过其 拥有的选举票数。 本次股东大会的议案 6.00 需经出席会议的股东所持表决权的三分之二以上 通过，其他议案需经出席会议的股东所持表决权的二分之一以上通过。其中，议 案 6.00，公司限制性股票激励计划（第一期）的激励对象作为关联股东，对该议 案回避表决。 国新健康保障服务集团股份有限公司（以下简称"公司"）于 2025 年 3 月 26 日召开第十一届董事会第三十七次会议，审议通过了《关于召开公司 2025 年 第一次临时股东大会的议案》，公司已于 ...